Susquehanna Financial Initiates Meridian Bioscience Inc. (VIVO) with a Neutral
More News related to VIVO
- Hilliard Lyons Upgrades Meridian Bioscience (VIVO) to Long-Term Buy
- Meridian Bioscience (VIVO) Reports In-Line Q3 EPS of $0.19; Guides
- Meridian Bioscience Reports Record Operating Results, Declares Regular Cash Dividend, Reaffirms Fiscal 2008 Guidance, and Comments on Fiscal 2009 Outlook
- Fortune Small Business Lists Meridian Bioscience as One of America's Fastest-Growing Small Companies
- Meridian Bioscience Completes Acquisition of Recombinant Protein Technologies and Products from Vybion, Inc.
More News related to New Coverage
- CL King Starts Powerwave (PWAV) at Accumulate
- BMO Starts MAG Silver (MVG) at Outperform
- Morgan Keegan Starts Hanesbrands (HBI) at Outperform
- Wachovia Initiates MDC Partners (MDCA) with an Outperform
- Piper Jaffray Initiates Boston Scientific (BSX) with a Buy
Susquehanna Financial initiates coverage on Meridian Bioscience Inc. (NASDAQ: VIVO) with a Neutral rating. The firm believes upside will be limited in the next year due to pressure on gross margins. After its 9.3% decline in 2QFY08, analysts would also like to see a new sales baseline established for the Life Sciences segment. The firm will become positive on VIVO when they see evidence the recent trend in VIVO’s gross margins is temporary.
Meridian Bioscience, Inc., a life science company, engages in the development, manufacture, sale, and distribution of diagnostic test kits primarily for respiratory, gastrointestinal, viral, and parasitic infectious diseases.
Related Categories
New CoverageStocks Mentioned
+0.47Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
